Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study

Study:

n/a

Rationale:

n/a

Purpose:

The AMPLATZER Muscular VSD Occluder was approved by the US Food and Drug Administration (FDA) in September, 2007. This study is designed to further evaluate the safety and effectiveness in subjects implanted with the AMPLATZER Muscular VSD Occluder.

Study Status: Recruiting

Recruiting:
Lourdes Prieto, MD

Condition Intervention Phase
Ventricular Septal Defects Device: Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder) N/A

Verified by AGA Medical Corporation December, 2013

Sponsored by: AGA Medical Corporation
Information provided by: AGA Medical Corporation
ClinicalTrials.gov identifier: NCT00647387

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

The Children`s Hospital at Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site